Patrys Limited (ASX: PAB) should trade higher revealing that four of eleven patients with end-stage, multi-resistant multiple myeloma have shown evidence of disease stabilisation during treatment with its PAT-SM6 anti-cancer drug.
To date eleven out of a total of twelve patients are currently available for response evaluation, including two out of three from the 4th and final treatment group.
The eleven patients, 9 male and 2 female, median age 71 years, had on average received five prior lines of therapy including autologous stem cell transplantation and other novel compounds.
Therapeutic options for such patients are usually limited to clinical trials and their median overall survival is around nine months.
All of the eleven evaluable patients tolerated PAT-SM6 well, without drug-related serious adverse events or dose-limiting toxicities.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.